



Bionest further boosts pharma consulting activity

Appointment of Lionel Delaporte and expansion of pharma team will help maintain Bionest revenue growth – up 50 percent in 2005

Paris and New York, August 29 2006--Bionest Partners, a provider of advisory and management services to life science companies, announces today the appointment of Lionel Delaporte as director and head of the pharmaceutical practice.

Lionel Delaporte, 39, brings experience and knowledge acquired over many years with leading consulting and research firms. In his new post, he is responsible for building up Bionest consulting activities in the worldwide pharmaceutical industry, ensuring quality and added value.

"The arrival of Lionel underscores Bionest's commitment to the pharmaceutical industry," said Claude Allary, managing partner and co-founder of Bionest, and himself an experienced professional in the field of big pharma. "We have known each other for some time and will together manage a first rate team in the pharmaceutical arena."

Bionest Partners' unique profile is based on its exclusive focus on healthcare, its ability to drill down to identify and analyze relevant information, and its recognition of key role of financial considerations. It employs this approach for all strategic missions to accelerate "top-line" growth for pharmaceutical companies while at the same time optimizing their "bottom line".

Bionest regularly carries out research and analysis of various therapeutic areas and managerial issues in life sciences. Recent reports compiled by Bionest and downloadable from its website include:

- Oncology Pipelines: Searching is not finding – a critical analysis and evaluation of oncology pipelines
- Vaccine Growth Boosters - an analysis of the levers of growth and the worldwide outlook for the vaccine markets.

Lionel Delaporte held management positions from 2000 to 2006 in three strategic healthcare consulting firms (ISO Health Care Consulting, Monitor and Smart Pharma Consulting). Between 1992 and 1999, he occupied various posts in IMS Health, including Director of International and Strategic Studies, and Director of Global Key Accounts Management. His consulting projects covered mainly strategy, operations and organization, and were carried out in close cooperation with companies such as Amgen, Altana, AstraZeneca, Bayer, BMS,

J&J, MSD, Pfizer, Roche, Sanofi-Aventis, Sanofi Pasteur, Schering-Plough and Serono. He has an MBA from the Institut Supérieur de Gestion.

About Bionest Partners

Bionest Partners provides advisory and management services to help pharmaceutical, biotechnology, specialty pharma and medical device companies and their shareholders maximize the value of their assets. The company was founded in 1996 and its managing partners are Alain J. Gilbert, Claude Allary and Frédéric Desdouits. Based in Paris, with offices in New York, it has a broad customer base ranging from biotech start-ups to established companies in the biotech, medical device and pharmaceuticals fields. Bionest Partners has experience with around 70 clients including Alexion, Aventis Pasteur, CSL, Gambro, GlaxoSmithKline, Idenix, Javelin, Millennium, Novartis, Pfizer, ProStrakan, Stallergènes and UCB. The company offers a hands-on approach, and its areas of expertise include management consulting (strategy, organization, marketing, due diligence, surrogate management), corporate finance (asset valuation, IPO support, out-licensing, in-licensing, mergers and acquisitions), entry into Europe (assessment, strategy, go-it-alone/partnering, management support). The company has a strong and growing team of more than 20 consultants as well as a network of associate members, mainly former CEOs and CXOs, which it deploys to address specific client assignments.

For more information on Bionest Partners: www.bionest.com

Press and Analysts Contacts

Andrew Lloyd & Associates

Andrew Lloyd / Neil Hunter

+44 1273 675 100

allo@ala.com / neil@ala.com

Bionest Partners

Thomas Martinelli

+ 33 1 58 05 14 00

thomas@bionest.com
